Trial NCT04296942

View at ClinicalTrials.gov 
Org. Study IDs: 200056
Secondary IDs: 20-C-0056

Last trial update was posted on 2022-01-11

MeSH Interventions

Ado-Trastuzumab Emtansine Entinostat Maytansine Trastuzumab

MeSH Conditions

Breast Neoplasms Triple Negative Breast Neoplasms

Other Conditions

Breast Cancer HER2+ Breast Cancer Hormone Receptor Negative Breast Cancer Metastatic Breast Cancer Triple Negative Breast Cancer

Stopping Reasons

One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID